论文部分内容阅读
对20例小儿白血病患者经诱导缓解后,行大剂量阿糖胞苷治疗,毒副反应以骨髓抑制较为明显,其中白细胞下降最为显著,血小板次之;临床发生感染4例,但无明显出血。本组累积剂量ALL为24.63±3.32g/m~2,ANLL为32±5.66g/m~2,未见明显神经毒性,除可能与年龄相关外,同时与Ara-c的累积剂量及滴注方式有关。应用时充分水化、碱化,积极支持,可安全度过骨髓抑制期,同时注意其累积剂量,持续、缓慢滴注可避免神经毒性的发生。
After 20 cases of pediatric leukemia were induced remission after high-dose cytarabine treatment, bone marrow toxicity was more obvious side effects, including the most significant leukopenia, followed by platelets; 4 cases of clinical infection, but no significant bleeding. Cumulative dose ALL in this group was 24.63 ± 3.32g / m ~ 2, ANLL was 32 ± 5.66g / m ~ 2, no obvious neurotoxicity, except possibly related to age, at the same time with the cumulative dose of Ara-c and instillation Related to the way When fully applied hydration, alkalinization, and actively support, can safely over the bone marrow suppression period, while paying attention to the cumulative dose, sustained and slow infusion can prevent the occurrence of neurotoxicity.